Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab vs Mitomycin-C/5-FU with Radiation in HNSCC
NCT02015650Phase 4Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Quality of Life at 3 years. Started Apr 2014; status: terminated.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02015650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015650.